WELCOME to epgonline.org

Access trusted, independent sources of clinical content for the United Kingdom as well as other regions. Registration is quick and simple, providing you with unlimited access to all content and features.
 

Latest News

Added 8 hours ago Drug news

NEJM publishes clinical details of larotrectinib, a treatment for TRK Fusion cancers.-Loxo Oncology + Bayer.

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, and...

Added 8 hours ago Drug news

CLAIM study of Ultibro Breezhaler shows reduction of lung hyperinflation in COPD patients.-Novartis.

Novartis announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro Breezhaler...

Added 1 day ago Drug news

FDA indicates way forward for ataluren application to treat Duchenne muscular dystrophy.- Translarna.

PTC Therapeutics announced that the Office of New Drugs of the FDA has reiterated the FDA's prior position and denied...

Search all news articles
 

WHAT'S ON THE HORIZON?

Marshall Pearce

How close are we to a disease-modifying treatment for Alzheimer’s?

Posted 2 months ago

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.

Penny Staton

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

Posted 4 months ago

An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 8 months ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Marshall Pearce

Cancer immunotherapies

Posted 10 months ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 10 months ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Latest Journal Abstracts

Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?

Area covered: This review is of semaglutide in type 2 diabetes, and considers which properties of this GLP-1R agonist, may be responsible for its clinical outcome benefits in this condition.

Added 1 day ago

Semaglutide: First Global Approval.

Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus.

Added 1 day ago

Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.

This manuscript describes semaglutide – a new investigational long acting GLP-1 receptor agonist. The key trials from the clinical development process are reviewed and important end-points highlighted.

Added 1 day ago

Latest Guidelines

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and longterm treatment of mixed states in bipolar disorder

This WFSBP guideline has been developed to supply a systematic overview of all scientific evidence pertaining to the acute and longterm treatment of bipolar mixed states in adults.

Added 3 months ago

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

In this document, the term ‘peripheral arterial diseases’ encompasses all arterial diseases other than coronary arteries and the aorta. This should be clearly distinguished from the term ‘peripheral artery disease’...

Added 2 months ago

Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)

The European Society for Vascular Surgery (ESVS) has prepared guidelines for treating patients with atherosclerotic carotid and vertebral artery (VA) disease.

Added 2 months ago

Latest Clinical Trials

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive...

Added 3 months ago

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Added 3 months ago

Multiple Cardiac Sensors for the Management of Heart Failure (MANAGE-HF)

The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.

Added 4 months ago

Search all clinical trials